{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:17:01Z","timestamp":1788337021896,"version":"build-2803163510"},"reference-count":112,"publisher":"Elsevier BV","issue":"8-9","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progr\u00e8s en Urologie"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.purol.2020.09.026","type":"journal-article","created":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T05:35:33Z","timestamp":1621834533000},"page":"458-476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Recommandations pratiques pour la prise en charge du d\u00e9ficit en testost\u00e9rone"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9386-7193","authenticated-orcid":false,"given":"C.","family":"Burte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Lejeune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Faix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Desvaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Almont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Cuzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9445-4385","authenticated-orcid":false,"given":"E.","family":"Huyghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3705","key":"10.1016\/j.purol.2020.09.026_bib0570","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1136\/bmj.1.3705.50","article-title":"The accidents of the male climacteric","volume":"1","author":"Walter","year":"1932","journal-title":"Br Med J"},{"issue":"8","key":"10.1016\/j.purol.2020.09.026_bib0575","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1001\/jama.1944.02850430006003","article-title":"The male climacteric, its symptomatology, diagnosis and treatment: use of urinary gonadotropins, therapeutic test with testosterone propionate and testicular biopsies in delineating the male climacteric from psychoneurosis and psychogenic impotence","volume":"126","author":"Heller","year":"1944","journal-title":"J Am Med Assoc"},{"issue":"5","key":"10.1016\/j.purol.2020.09.026_bib0580","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1210\/jcem-59-5-955","article-title":"Leydig cell function in normal men: effect of age, life-style, residence, diet, and activity","volume":"59","author":"Deslypere","year":"1984","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.purol.2020.09.026_bib0585","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1210\/er.2004-0013","article-title":"The decline of androgen levels in elderly men and its clinical and therapeutic implications","volume":"26","author":"Kaufman","year":"2005","journal-title":"Endocr Rev"},{"issue":"1","key":"10.1016\/j.purol.2020.09.026_bib0590","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/BF03034404","article-title":"R\u00e9flexion multidisciplinaire sur la prise en charge du d\u00e9ficit androg\u00e9nique li\u00e9 \u00e0 l\u2019\u00e2ge","volume":"13","author":"Buvat","year":"2003","journal-title":"Andrologie"},{"issue":"2","key":"10.1016\/j.purol.2020.09.026_bib0595","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/tam.5.2.74.86","article-title":"Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM. International Society for the Study of the Aging Male","volume":"5","author":"Morales","year":"2002","journal-title":"Aging Male"},{"issue":"4","key":"10.1016\/j.purol.2020.09.026_bib0600","first-page":"289","article-title":"[Investigation, treatment and monitoring of late-onset hypogonadism in males: the official guidelines of the International Society for the Study of the Study of the Aging Male (ISSAM) with comments]","volume":"64","author":"Cuzin","year":"2003","journal-title":"Ann Endocrinol"},{"issue":"1","key":"10.1016\/j.purol.2020.09.026_bib0605","first-page":"1","article-title":"Diagnostic, traitement et surveillance de l\u2019hypogonadisme de survenue tardive chez l\u2019homme\u00a0: recommandations officielles de l\u2019International Society for the Study of the Aging Male (ISSAM) et commentaires","volume":"14","author":"Cuzin","year":"2004","journal-title":"Prog Urol"},{"issue":"5","key":"10.1016\/j.purol.2020.09.026_bib0610","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1530\/EJE-08-0601","article-title":"Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations","volume":"159","author":"Wang","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.purol.2020.09.026_bib0615","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.eururo.2008.08.033","article-title":"Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations","volume":"55","author":"Wang","year":"2009","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.purol.2020.09.026_bib0620","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2164\/jandrol.108.006486","article-title":"Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations","volume":"30","author":"Wang","year":"2009","journal-title":"J Androl"},{"issue":"1","key":"10.1016\/j.purol.2020.09.026_bib0625","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ijir.2008.41","article-title":"ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males","volume":"21","author":"Wang","year":"2009","journal-title":"Int J Impot Res"},{"issue":"1","key":"10.1016\/j.purol.2020.09.026_bib0630","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/13685530802389628","article-title":"ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males","volume":"12","author":"Wang","year":"2009","journal-title":"Aging Male"},{"issue":"1","key":"10.1016\/j.purol.2020.09.026_bib0635","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2605.2008.00924.x","article-title":"Investigation, treatment and monitoring of late-onset hypogonadism in males","volume":"32","author":"Wang","year":"2009","journal-title":"Int J Androl"},{"issue":"4","key":"10.1016\/j.purol.2020.09.026_bib0640","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1210\/er.2018-00178","article-title":"Aging and the male reproductive system","volume":"40","author":"Kaufman","year":"2019","journal-title":"Endocr Rev"},{"issue":"8","key":"10.1016\/j.purol.2020.09.026_bib0645","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1111\/jsm.12952","article-title":"The International Society for Sexual Medicine's process of care for the assessment and management of testosterone deficiency in adult men","volume":"12","author":"Dean","year":"2015","journal-title":"J Sex Med"},{"issue":"1","key":"10.1016\/j.purol.2020.09.026_bib0650","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3109\/13685538.2015.1004049","article-title":"Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men","volume":"18","author":"Lunenfeld","year":"2015","journal-title":"Aging Male"},{"issue":"12","key":"10.1016\/j.purol.2020.09.026_bib0655","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.jsxm.2016.10.009","article-title":"Diagnosis and treatment of testosterone deficiency: recommendations from the Fourth International Consultation for Sexual Medicine (ICSM 2015)","volume":"13","author":"Khera","year":"2016","journal-title":"J Sex Med"},{"key":"10.1016\/j.purol.2020.09.026_bib0660","series-title":"Guidelines on male hypogonadism 2015","author":"Dohle","year":"2016"},{"issue":"12","key":"10.1016\/j.purol.2020.09.026_bib0665","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.jsxm.2017.10.067","article-title":"British Society for Sexual Medicine Guidelines on adult testosterone deficiency, with statements for UK practice","volume":"14","author":"Hackett","year":"2017","journal-title":"J Sex Med"},{"issue":"5","key":"10.1016\/j.purol.2020.09.026_bib0670","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1210\/jc.2018-00229","article-title":"Testosterone therapy in men with hypogonadism: an Endocrine Society Clinical practice guideline","volume":"103","author":"Bhasin","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.purol.2020.09.026_bib0675","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.juro.2018.03.115","article-title":"Evaluation and management of testosterone deficiency: AUA Guideline","volume":"200","author":"Mulhall","year":"2018","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.purol.2020.09.026_bib0680","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.sxmr.2019.06.003","article-title":"Diagnosis and treatment of testosterone deficiency: updated recommendations from the Lisbon 2018 International Consultation for Sexual Medicine","volume":"7","author":"Morgentaler","year":"2019","journal-title":"Sex Med Rev"},{"issue":"6","key":"10.1016\/j.purol.2020.09.026_bib0685","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jsxm.2019.03.262","article-title":"Testosterone deficiency: a review and comparison of current guidelines","volume":"16","author":"Kwong","year":"2019","journal-title":"J Sex Med"},{"issue":"5","key":"10.1016\/j.purol.2020.09.026_bib0690","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/bju.14899","article-title":"Guideline of guidelines: testosterone therapy for testosterone deficiency","volume":"124","author":"Salter","year":"2019","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.purol.2020.09.026_bib0695","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3390\/jcm8030410","article-title":"Evolution of guidelines for testosterone replacement therapy","volume":"8","author":"Park","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.purol.2020.09.026_bib0700","series-title":"Appraisal of guidelines for research & evaluation (AGREE) instrument","author":"Agree Collaboration","year":"2001"},{"key":"10.1016\/j.purol.2020.09.026_bib0705","series-title":"M\u00e9thode et processus d\u2019adaptation des recommandations pour la pratique clinique existantes. Guide M\u00e9thodologique","author":"Haute Autorit\u00e9 de sant\u00e9","year":"2007"},{"issue":"2","key":"10.1016\/j.purol.2020.09.026_bib0710","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3390\/jcm8020209","article-title":"The optimal indication for testosterone replacement therapy in late onset hypogonadism","volume":"8","author":"Shin","year":"2019","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.purol.2020.09.026_bib0715","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.mayocp.2016.04.022","article-title":"Adult-onset hypogonadism","volume":"91","author":"Khera","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.purol.2020.09.026_bib0720","series-title":"European Association of Urology guidelines on male hypogonadism","author":"Dohle","year":"2017"},{"issue":"12","key":"10.1016\/j.purol.2020.09.026_bib0725","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1210\/jc.2003-031719","article-title":"Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study","volume":"89","author":"Araujo","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.purol.2020.09.026_bib0730","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1210\/jc.2007-1245","article-title":"Prevalence of symptomatic androgen deficiency in men","volume":"92","author":"Araujo","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.purol.2020.09.026_bib0735","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0911101","article-title":"Identification of late-onset hypogonadism in middle-aged and elderly men","volume":"363","author":"Wu","year":"2010","journal-title":"N Engl J Med"},{"issue":"6 Pt 1","key":"10.1016\/j.purol.2020.09.026_bib0740","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1365-2605.2010.01117.x","article-title":"Type 2 diabetes mellitus and testosterone: a meta-analysis study","volume":"34","author":"Corona","year":"2011","journal-title":"Int J Androl"},{"issue":"7","key":"10.1016\/j.purol.2020.09.026_bib0745","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/j.1742-1241.2006.00992.x","article-title":"Prevalence of hypogonadism in males aged at least 45 years: the HIM study","volume":"60","author":"Mulligan","year":"2006","journal-title":"Int J Clin Pract"},{"issue":"12","key":"10.1016\/j.purol.2020.09.026_bib0750","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/sc.2017.73","article-title":"Prevalence of androgen deficiency in chronic spinal cord injury patients suffering from erectile dysfunction","volume":"55","author":"Behnaz","year":"2017","journal-title":"Spinal Cord"},{"issue":"1","key":"10.1016\/j.purol.2020.09.026_bib0755","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13685538.2016.1185408","article-title":"The relationship of salivary testosterone and male sexual dysfunction in opioid-associated androgen deficiency (OPIAD)","volume":"20","author":"Ajo","year":"2017","journal-title":"Aging Male"},{"key":"10.1016\/j.purol.2020.09.026_bib0760","series-title":"Guidelines on male hypogonadism","author":"Dohle","year":"2017"},{"issue":"1","key":"10.1016\/j.purol.2020.09.026_bib0765","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1743-6109.2012.02783.x","article-title":"Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment","volume":"10","author":"Buvat","year":"2013","journal-title":"J Sex Med"},{"issue":"4","key":"10.1016\/j.purol.2020.09.026_bib0770","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1210\/er.2017-00025","article-title":"A reappraisal of testosterone's binding in circulation: physiological and clinical implications","volume":"38","author":"Goldman","year":"2017","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1016\/j.purol.2020.09.026_bib0775","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3109\/13685538.2013.853731","article-title":"Recommendations on the diagnosis, treatment and monitoring of late-onset hypogonadism in men\u00a0\u2013\u00a0a suggested update","volume":"16","author":"Lunenfeld","year":"2013","journal-title":"Aging Male"},{"issue":"10","key":"10.1016\/j.purol.2020.09.026_bib0780","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1210\/jc.2011-1137","article-title":"Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis","volume":"96","author":"Araujo","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.purol.2020.09.026_bib0785","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/hrt.2010.210757","article-title":"Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis","volume":"97","author":"Ruige","year":"2011","journal-title":"Heart"},{"issue":"12","key":"10.1016\/j.purol.2020.09.026_bib0790","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1093\/eurheartj\/ehq009","article-title":"Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20\u201379","volume":"31","author":"Haring","year":"2010","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.purol.2020.09.026_bib0795","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1530\/EJE-13-0321","article-title":"Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes","volume":"169","author":"Muraleedharan","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.purol.2020.09.026_bib0800","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jamda.2013.12.004","article-title":"Hormones and cardiovascular disease in older men","volume":"15","author":"Yeap","year":"2014","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.purol.2020.09.026_bib0805","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12902-015-0034-1","article-title":"Low concentrations of serum testosterone predict acute myocardial infarction in men with type 2 diabetes mellitus","volume":"15","author":"Daka","year":"2015","journal-title":"BMC Endocr Disord"},{"issue":"3","key":"10.1016\/j.purol.2020.09.026_bib0810","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.sxmr.2017.02.002","article-title":"The Graham Jackson Memorial Lecture ISSM 2016\u00a0\u2013\u00a0\u201cThe Man Who Knew Too Much?: time to recognize erectile dysfunction and low testosterone as independent risk factors for cardiovascular disease","volume":"5","author":"Hackett","year":"2017","journal-title":"Sex Med Rev"},{"issue":"2","key":"10.1016\/j.purol.2020.09.026_bib0815","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/1756287215617648","article-title":"An update on the role of testosterone replacement therapy in the management of hypogonadism","volume":"8","author":"Hackett","year":"2016","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.purol.2020.09.026_bib0820","doi-asserted-by":"crossref","first-page":"683515","DOI":"10.1155\/2014\/683515","article-title":"Effects of long-term testosterone therapy on patients with \u201cdiabesity?: results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes","volume":"2014","author":"Haider","year":"2014","journal-title":"Int J Endocrinol"},{"issue":"2","key":"10.1016\/j.purol.2020.09.026_bib0825","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40264-015-0348-y","article-title":"Testosterone replacement therapy and mortality in older men","volume":"39","author":"Hackett","year":"2016","journal-title":"Drug Saf"},{"issue":"2","key":"10.1016\/j.purol.2020.09.026_bib0830","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1000485","article-title":"Adverse events associated with testosterone administration","volume":"363","author":"Basaria","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.purol.2020.09.026_bib0835","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.steroids.2014.05.004","article-title":"Outcomes of testosterone therapy in men with testosterone deficiency (TD): part II","volume":"88","author":"Traish","year":"2014","journal-title":"Steroids"},{"issue":"5","key":"10.1016\/j.purol.2020.09.026_bib0840","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/1074248417691136","article-title":"Long-term testosterone therapy improves cardiometabolic function and reduces risk of cardiovascular disease in men with hypogonadism: a real-life observational registry study setting comparing treated and untreated (control) groups","volume":"22","author":"Traish","year":"2017","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.purol.2020.09.026_bib0845","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4239\/wjd.v8.i3.104","article-title":"Statin, testosterone and phosphodiesterase 5-inhibitor treatments and age related mortality in diabetes","volume":"8","author":"Hackett","year":"2017","journal-title":"World J Diabetes"},{"issue":"3","key":"10.1016\/j.purol.2020.09.026_bib0850","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/ijcp.12779","article-title":"Serum testosterone, testosterone replacement therapy and all-cause mortality in men with type 2 diabetes: retrospective consideration of the impact of PDE5 inhibitors and statins","volume":"70","author":"Hackett","year":"2016","journal-title":"Int J Clin Pract"},{"issue":"40","key":"10.1016\/j.purol.2020.09.026_bib0855","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1093\/eurheartj\/ehv346","article-title":"Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men","volume":"36","author":"Sharma","year":"2015","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.purol.2020.09.026_bib0860","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1177\/1060028014539918","article-title":"Risk of myocardial infarction in older men receiving testosterone therapy","volume":"48","author":"Baillargeon","year":"2014","journal-title":"Ann Pharmacother"},{"issue":"5","key":"10.1016\/j.purol.2020.09.026_bib0865","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.amjcard.2015.11.063","article-title":"Impact of testosterone replacement therapy on myocardial infarction, stroke, and death in men with low testosterone concentrations in an integrated health care system","volume":"117","author":"Anderson","year":"2016","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.purol.2020.09.026_bib0870","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S2213-8587(16)00112-1","article-title":"Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study","volume":"4","author":"Wallis","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.purol.2020.09.026_bib0875","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jamainternmed.2016.9546","article-title":"Association of testosterone replacement with cardiovascular outcomes among men with androgen deficiency","volume":"177","author":"Cheetham","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"6","key":"10.1016\/j.purol.2020.09.026_bib0880","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1210\/jc.2011-2591","article-title":"Testosterone treatment and mortality in men with low testosterone levels","volume":"97","author":"Shores","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.purol.2020.09.026_bib0885","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.beem.2013.05.002","article-title":"Diagnosis and treatment of late-onset hypogonadism: systematic review and meta-analysis of TRT outcomes","volume":"27","author":"Corona","year":"2013","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.purol.2020.09.026_bib0890","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.amjmed.2016.09.017","article-title":"Cardiovascular risks of exogenous testosterone use among men: a systematic review and meta-analysis","volume":"130","author":"Alexander","year":"2017","journal-title":"Am J Med"},{"issue":"9","key":"10.1016\/j.purol.2020.09.026_bib0895","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.jsxm.2018.06.012","article-title":"Endogenous testosterone levels and cardiovascular risk: meta-analysis of observational studies","volume":"15","author":"Corona","year":"2018","journal-title":"J Sex Med"},{"issue":"9","key":"10.1016\/j.purol.2020.09.026_bib0900","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1080\/14779072.2018.1510314","article-title":"Cardiovascular impact of testosterone therapy for hypogonadism","volume":"16","author":"Rastrelli","year":"2018","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"8","key":"10.1016\/j.purol.2020.09.026_bib0905","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.mayocp.2015.05.012","article-title":"Risk of Venous thromboembolism in men receiving testosterone therapy","volume":"90","author":"Baillargeon","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.purol.2020.09.026_bib0910","doi-asserted-by":"crossref","first-page":"i5968","DOI":"10.1136\/bmj.i5968","article-title":"Testosterone treatment and risk of venous thromboembolism: population based case-control study","volume":"355","author":"Martinez","year":"2016","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.purol.2020.09.026_bib0915","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1177\/1076029615619486","article-title":"Thrombophilia in 67 patients with thrombotic events after starting testosterone therapy","volume":"22","author":"Glueck","year":"2016","journal-title":"Clin Appl Thromb Hemost"},{"issue":"2","key":"10.1016\/j.purol.2020.09.026_bib0920","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/jamainternmed.2019.5135","article-title":"Association of testosterone therapy with risk of venous thromboembolism among men with and without hypogonadism","volume":"180","author":"Walker","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.purol.2020.09.026_bib0925","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.thromres.2018.10.023","article-title":"Testosterone therapy and venous thromboembolism: a systematic review and meta-analysis","volume":"172","author":"Houghton","year":"2018","journal-title":"Thromb Res"},{"issue":"10","key":"10.1016\/j.purol.2020.09.026_bib0930","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1210\/jc.2010-0864","article-title":"Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis","volume":"95","author":"Bachman","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.purol.2020.09.026_bib0935","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.2047-2927.2012.00009.x","article-title":"Is the haematopoietic effect of testosterone mediated by erythropoietin? The results of a clinical trial in older men","volume":"1","author":"Maggio","year":"2013","journal-title":"Andrology"},{"issue":"1","key":"10.1016\/j.purol.2020.09.026_bib0940","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.sxmr.2017.08.007","article-title":"Low serum testosterone in outpatient psychiatry clinics: addressing challenges to the screening and treatment of hypogonadism","volume":"6","author":"Smith","year":"2018","journal-title":"Sex Med Rev"},{"issue":"7","key":"10.1016\/j.purol.2020.09.026_bib0945","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1111\/j.1743-6109.2010.01859.x","article-title":"Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome","volume":"7","author":"Giltay","year":"2010","journal-title":"J Sex Med"},{"issue":"1","key":"10.1016\/j.purol.2020.09.026_bib0950","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3109\/13685538.2011.606513","article-title":"The effect of testosterone supplementation on depression symptoms in hypogonadal men from the Testim Registry in the US (TRiUS)","volume":"15","author":"Khera","year":"2012","journal-title":"Aging Male"},{"issue":"14","key":"10.1016\/j.purol.2020.09.026_bib0955","doi-asserted-by":"crossref","first-page":"7537","DOI":"10.1073\/pnas.94.14.7537","article-title":"Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor 1 to growth hormone","volume":"94","author":"Morley","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.purol.2020.09.026_bib0960","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12603-012-0002-7","article-title":"The hormonal pathway to cognitive impairment in older men","volume":"16","author":"Maggio","year":"2012","journal-title":"J Nutr Health Aging"},{"issue":"19","key":"10.1016\/j.purol.2020.09.026_bib0965","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1001\/jama.296.19.2351","article-title":"Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial","volume":"296","author":"Marks","year":"2006","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.purol.2020.09.026_bib0970","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.juro.2017.07.039","article-title":"Long-term testosterone therapy improves urinary and sexual function, and quality of life in men with hypogonadism: results from a propensity matched subgroup of a controlled registry study","volume":"199","author":"Haider","year":"2018","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.purol.2020.09.026_bib0975","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/luts.12150","article-title":"Serum testosterone levels are negatively correlated with International Prostate Symptom Score and transitional prostate volume","volume":"10","author":"Shim","year":"2018","journal-title":"Low Urin Tract Symptoms"},{"issue":"1","key":"10.1016\/j.purol.2020.09.026_bib0980","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000447187","article-title":"The effect of transdermal testosterone administration on lower urinary tract symptoms and erectile dysfunction: a prospective, randomized, placebo-controlled trial","volume":"11","author":"Yucel","year":"2017","journal-title":"Curr Urol"},{"issue":"6","key":"10.1016\/j.purol.2020.09.026_bib0985","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1210\/jcem.82.6.3988","article-title":"Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial","volume":"82","author":"Sih","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.purol.2020.09.026_bib0990","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/j.1532-5415.2010.02865.x","article-title":"Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty","volume":"58","author":"Kenny","year":"2010","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"10.1016\/j.purol.2020.09.026_bib0995","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11934-016-0600-8","article-title":"Testosterone replacement therapy and BPH\/LUTS. What is the evidence?","volume":"17","author":"Baas","year":"2016","journal-title":"Curr Urol Rep"},{"issue":"6","key":"10.1016\/j.purol.2020.09.026_bib1000","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.eururo.2016.01.043","article-title":"Effects of testosterone replacement therapy on lower urinary tract symptoms: a systematic review and meta-analysis","volume":"69","author":"Kohn","year":"2016","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.purol.2020.09.026_bib1005","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ucl.2016.04.011","article-title":"Testosterone and the prostate: artifacts and truths","volume":"43","author":"DeLay","year":"2016","journal-title":"Urol Clin North Am"},{"issue":"5","key":"10.1016\/j.purol.2020.09.026_bib1010","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1177\/1557988316652843","article-title":"Improved lower urinary tract symptoms associated with testosterone replacement therapy in japanese men with late-onset hypogonadism","volume":"12","author":"Okada","year":"2018","journal-title":"Am J Mens Health"},{"issue":"3","key":"10.1016\/j.purol.2020.09.026_bib1015","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1177\/1740774514524032","article-title":"The testosterone trials: seven coordinated trials of testosterone treatment in elderly men","volume":"11","author":"Snyder","year":"2014","journal-title":"Clin Trials"},{"issue":"9","key":"10.1016\/j.purol.2020.09.026_bib1020","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/aje\/kwz138","article-title":"Testosterone replacement therapy and the risk of prostate cancer in men with late-onset hypogonadism","volume":"188","author":"Santella","year":"2019","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.purol.2020.09.026_bib1025","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1158\/1055-9965.EPI-05-0633","article-title":"Circulating steroid hormones and the risk of prostate cancer","volume":"15","author":"Severi","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"10.1016\/j.purol.2020.09.026_bib1030","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ijc.11572","article-title":"High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study","volume":"108","author":"Stattin","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.purol.2020.09.026_bib1035","first-page":"297","article-title":"Studies on prostatic cancer","volume":"1","author":"Huggins","year":"1941","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.purol.2020.09.026_bib1040","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.eururo.2008.09.024","article-title":"Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth","volume":"55","author":"Morgentaler","year":"2009","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.purol.2020.09.026_bib1045","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.juro.2011.04.065","article-title":"Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory","volume":"186","author":"Khera","year":"2011","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.purol.2020.09.026_bib1050","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.juro.2013.02.002","article-title":"Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy","volume":"190","author":"Pastuszak","year":"2013","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.purol.2020.09.026_bib1055","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.juro.2015.05.084","article-title":"Testosterone therapy after radiation therapy for low, intermediate and high risk prostate cancer","volume":"194","author":"Pastuszak","year":"2015","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.purol.2020.09.026_bib1060","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4103\/1008-682X.160270","article-title":"Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results","volume":"18","author":"Kacker","year":"2016","journal-title":"Asian J Androl"},{"key":"10.1016\/j.purol.2020.09.026_bib1065","series-title":"Guidelines on male hypogonadism","author":"Dohle","year":"2018"},{"issue":"12","key":"10.1016\/j.purol.2020.09.026_bib1070","first-page":"4500","article-title":"Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men","volume":"85","author":"Swerdloff","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"17","key":"10.1016\/j.purol.2020.09.026_bib1075","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.2165\/00003495-200464170-00002","article-title":"Androgen replacement therapy: present and future","volume":"64","author":"Gooren","year":"2004","journal-title":"Drugs"},{"issue":"18","key":"10.1016\/j.purol.2020.09.026_bib1080","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1503\/cmaj.150033","article-title":"Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline","volume":"187","author":"Morales","year":"2015","journal-title":"CMAJ"},{"issue":"5","key":"10.1016\/j.purol.2020.09.026_bib1085","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.2337\/diacare.27.5.1036","article-title":"Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men","volume":"27","author":"Laaksonen","year":"2004","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.purol.2020.09.026_bib1090","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1210\/jc.2014-4184","article-title":"Associations between sex steroids and the development of metabolic syndrome: a longitudinal study in European men","volume":"100","author":"Antonio","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.purol.2020.09.026_bib1095","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1530\/JOE-12-0455","article-title":"Testosterone a metabolic hormone in health and disease","volume":"217","author":"Kelly","year":"2013","journal-title":"J Endocrinol"},{"issue":"3","key":"10.1016\/j.purol.2020.09.026_bib1100","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s11154-015-9323-2","article-title":"The complex and multifactorial relationship between testosterone deficiency (TD), obesity and vascular disease","volume":"16","author":"Traish","year":"2015","journal-title":"Rev Endocr Metab Disord"},{"issue":"3","key":"10.1016\/j.purol.2020.09.026_bib1105","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/ijcp.12319","article-title":"Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study","volume":"68","author":"Traish","year":"2014","journal-title":"Int J Clin Pract"},{"issue":"1","key":"10.1016\/j.purol.2020.09.026_bib1110","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ijo.2015.139","article-title":"Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies","volume":"40","author":"Saad","year":"2016","journal-title":"Int J Obes (Lond)"},{"issue":"2","key":"10.1016\/j.purol.2020.09.026_bib1115","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.sxmr.2017.01.003","article-title":"Testosterone replacement therapy and components of the metabolic syndrome","volume":"5","author":"Anaissie","year":"2017","journal-title":"Sex Med Rev"},{"issue":"5","key":"10.1016\/j.purol.2020.09.026_bib1120","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1530\/EJE-11-0221","article-title":"Onset of effects of testosterone treatment and time span until maximum effects are achieved","volume":"165","author":"Saad","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"3\u20134","key":"10.1016\/j.purol.2020.09.026_bib1125","article-title":"UK policy statements on testosterone deficiency","volume":"71","author":"Hackett","year":"2017","journal-title":"Int J Clin Pract"}],"container-title":["Progr\u00e8s en Urologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708720307430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708720307430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T06:34:11Z","timestamp":1761114851000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1166708720307430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":112,"journal-issue":{"issue":"8-9","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S1166708720307430"],"URL":"https:\/\/doi.org\/10.1016\/j.purol.2020.09.026","relation":{},"ISSN":["1166-7087"],"issn-type":[{"value":"1166-7087","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommandations pratiques pour la prise en charge du d\u00e9ficit en testost\u00e9rone","name":"articletitle","label":"Article Title"},{"value":"Progr\u00e8s en Urologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.purol.2020.09.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}